...A. We delivered some extraordinary clinical data for RVT-3101, our anti-TL1A antibody in ulcerative colitis, both at the beginning of the year in the induction phase and in June in the maintenance phase. B. We announced the first cut of the IMVT-1402 healthy volunteers, SAD and MAD data in September and showed a profile that we believe sets us up to have a potentially best-in-class anti-FcRn antibody with batoclimab-like IgG suppression and at least in the cohort shown so far, no impact on LDL or albumin and that's all sort of up until now. C. So on the next slide, I just want to talk a little bit about the acquisition here that we've already messaged, which is that the plan here is for us to sell Telavant, our anti-TL1A antibody program to Roche. D. The sale was for $7.1 billion upfront with a [$115] million milestone....
